Influence of psychopathology and metabolic parameters on quality of life in patients with first-episode psychosis before and after initial antipsychotic treatment

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 498 KB, PDF-dokument

The impact of psychological and physical health on quality of life (QoL) in patients with early psychosis remain relatively unexplored. We evaluated the predictive value of psychopathological and metabolic parameters on QoL in antipsychotic-naïve patients with first-episode psychosis before and after initial antipsychotic treatment. At baseline, 125 patients underwent assessments of psychopathology, prevalence of metabolic syndrome (MetS), and QoL. After 6 weeks of antipsychotic monotherapy, 89 patients were re-investigated. At baseline, the prevalence of MetS was 19.3% (n = 22). After 6 weeks, body weight (1.3 kg, p < 0.001) and body mass index (0.4 kg/m2, p < 0.001) increased, and four additional patients developed MetS. Multivariate linear regression revealed that positive and negative symptoms, and to some degree waist circumference, were predictors of QoL at both time points. Our findings suggest that in the earliest stages of antipsychotic treatment, metabolic side-effects may be less influential on QoL than psychopathological severity.
OriginalsprogEngelsk
Artikelnummer76
TidsskriftSchizophrenia
Vol/bind9
Udgave nummer1
Antal sider7
ISSN2334-265X
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
We would like to thank patients for their participation in this study, and the Lundbeck Foundation for granting a scholar-stipendium to AD (grant reference number: R377-2021-340).

Funding Information:
A.D. was funded by a scholarship from the Lundbeck Foundation. K.B. received a lecture fee from Lundbeck Pharma A/S. B.G. has been the leader of the Lundbeck Foundation Center of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009–December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and are administrated by them. She has no other conflicts to disclose. M.H. received speaker and advisory board fees from Alkermes. She has also received funding to support visiting professorships to Denmark from the Novo Nordisk Fonden, and the Danish Diabetes Association. B.E. is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. The Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS is funded by Lundbeck Foundation grant number R25-A2701. The other authors declare no conflict of interest.

Publisher Copyright:
© 2023, The Author(s).

ID: 373871456